

11. Why Inflammation Does Not Stop

Absurd Health Institute | Medical Concept Papers, Volume Four | III. When inflammation refuses to end

Publication type: Revised medical concept and hypothesis essay — not peer reviewed **Corrective edition:** 17 October 2026 **Substantive text:** 1,310 words

Abstract

Acute inflammation is usually terminated by active processes, not merely exhaustion of its initiating signal. Failure of resolution may be one maintaining mechanism in selected chronic inflammatory conditions, with crucial distinctions between unresolved infection, dysregulated immunity and structural injury.

Acute inflammation is usually terminated by active processes, not merely exhaustion of its initiating signal. Failure of resolution may be one maintaining mechanism in selected chronic inflammatory conditions, with crucial distinctions between unresolved infection, dysregulated immunity and structural injury.

Beginning and ending are different programs

The inflammatory response recruits cells and mediators to contain a threat and initiate repair. Successful recovery does not simply mean the disappearance of the initial pathogen-associated signal. Neutrophil influx must decline, dying cells must be cleared, macrophage programs must change, and tissue architecture must be rebuilt. Lipid mediators including lipoxins, resolvins, protectins and maresins have been implicated in regulation of resolution. Their existence supports an active-resolution model; it does not show that supplementation with their precursors cures chronic inflammatory disease.

Persistence may have several distinct meanings

A patient can remain inflamed because an antigen or microorganism persists, because an autoimmune process is maintained, because tissue continues releasing damage-associated signals, or because the terminating machinery is ineffective. These possibilities overlap but are not interchangeable. For example, treating uncontrolled infection as purely failed resolution could be dangerous; suppressing immunity without recognizing a pathogen can worsen the underlying illness.

The termination checkpoint

An important cellular event is efficient efferocytosis, the uptake of apoptotic cells before they undergo secondary necrosis. Failure can leave inflammatory material within tissue and help sustain recruitment. In atherosclerotic plaque, evidence links defective macrophage corpse clearance to necrotic core development and lesion progression. This is a focused example where termination failure contributes to a clinically consequential disease pathway.

An original explanatory framework

We propose distinguishing four phases: recognition, amplification, containment and resolution/remodeling. Chronic disease can emerge because amplification exceeds control, containment fails, the threatening stimulus remains, or resolution/remodeling is incomplete. This prevents the phrase 'chronic inflammation' from functioning as if it named a unique cause. It also encourages asking why apparently successful control of an upstream variable does not necessarily restore tissue function.

Discriminating the possibilities

The model would gain value if phase-specific measurements predict outcomes beyond circulating inflammatory markers. Demonstrations of persistent pathogen, altered efferocytosis, impaired pro-resolving signaling or irreversible fibrosis demand different interpretations. Randomly lowering an inflammatory laboratory value does not establish that resolution has occurred.

Safety and scope

This is not a recommendation to abandon anti-inflammatory medication. Such drugs can preserve organs and lives when used for the right disease. Conversely, attempts to 'stimulate resolution' without understanding infection or autoimmunity remain experimental. The strongest contribution is causal clarity: stopping an inflammatory process and rebuilding the injured tissue are linked but distinct tasks.

A resolution failure is not the same as immune deficiency

An immune system can be vigorous yet poorly coordinated. A tissue may recruit effector cells effectively but fail to remove them promptly, or it may clear dying cells poorly and prolong inflammatory exposure. The resulting process is not well described by either 'weak immunity' or 'strong immunity.' It is a failure of sequence and regulation. This distinction matters because treatments marketed as immune stimulation can be inappropriate in a disorder with excessive or misdirected immune activity.

Specific mediators and the danger of therapeutic extrapolation

Specialized pro-resolving lipid mediators have provided important mechanistic insight into how inflammatory programs terminate. They do not simply reproduce the effects of indiscriminate immunosuppression. Some promote the clearing of apoptotic cells and influence the trafficking of immune populations. Yet a compound's ability to stimulate resolution in an animal model is not proof of benefit in patients with rheumatoid arthritis, postviral symptoms or autoimmune thyroid disease. Drug formulation, pharmacokinetics, target tissue and unintended effects all matter.

Reading the phase of disease

In an early infection, vigorous microbial containment may be indispensable. After the threat is controlled, the unresolved inflammatory response may become relatively more important. In advanced fibrosis, structural injury may dominate even after inflammation subsides. These temporal distinctions suggest different questions for different clinical stages. The model is falsifiable when phase and outcome are defined, and dangerously vague when 'inflammation' is invoked as both cause and symptom without identifying the process.

Resolution is an active biological program

A stereotyped inflammatory response recruits cells, changes vascular permeability and mobilizes chemical signals to contain damage. The return toward homeostasis is not necessarily a passive fading of those signals. Neutrophils have to stop accumulating, apoptotic cells must be cleared, macrophage behavior changes, and damaged structures need repair. Specialized pro-resolving lipid mediators are among the investigated participants in this transition, alongside protein signals, changes in metabolism and the withdrawal of the original stimulus. The details differ among sterile injury, infection, autoimmune conditions and ordinary wound healing.

This distinction matters when an inflammatory marker remains elevated. An ongoing pathogen, an autoimmune response, dead tissue, a foreign body or failure of resolution may each be responsible, but the same marker cannot identify which. A drug that lowers a cytokine may improve a disease even if it does not eliminate the initiating process; in a different condition, suppressing immune defense may worsen infection. A theory about incomplete resolution must begin with a credible differential diagnosis rather than assuming that all persistent inflammation shares one defect.

Cell clearance and feedback loops

The accumulation of dying cells can release danger-associated signals when clearance is inadequate, potentially sustaining immune activation. Macrophage efferocytosis can help limit this process, but macrophages also have context-dependent roles in fibrosis and tissue remodeling. The same broad cell class can therefore participate in both recovery and chronic pathology. A simplistic switch from 'inflammatory' to 'healing' macrophages fails to capture the diversity of states observed in actual tissues.

Fibrosis adds a second loop. Activated fibroblasts deposit matrix, and stiff matrix can feed back through mechanical signaling to support further fibroblast activation. The persistence of disease may then depend partly on architecture, even when the earliest inflammatory signal has declined. This is not a universal explanation for every chronic inflammatory syndrome: some diseases continue because the immune system repeatedly encounters an antigen, while others are driven by genetic or metabolic abnormalities.

How to separate persistence from failed resolution

Longitudinal sampling is more informative than a single cytokine measurement. A useful study would track the initiating insult, recruited immune-cell populations, apoptotic-cell burden, pro-resolving pathways and organ function through the expected recovery interval. Comparison groups should include patients who recover normally and those with persistent disease, ideally matched for the severity of initial injury. Researchers would ask whether defective resolution precedes chronic symptoms and whether it remains significant after controlling for the amount of tissue destruction.

Intervention studies require equal caution. A proposed pro-resolving treatment should preserve host defense and improve functional outcomes rather than simply reducing a laboratory marker. Negative results may show that the putative defect is secondary or that established fibrosis has become the principal limitation. The real hypothesis is that recovery is a regulated biological phase with mechanisms that can fail. Whether a particular chronic disorder reflects such failure remains a disease-specific question.

The crucial transition is measurable

A wound that is no longer recruiting neutrophils may still contain dying cells, activated fibroblasts and altered matrix. Conversely, a tissue may remain inflamed because a pathogen continues to replicate. A useful resolution study therefore needs several concurrent observations rather than declaring that a falling cytokine concentration marks successful healing. Researchers could measure recruited and resident immune-cell populations, apoptotic-cell clearance, tissue perfusion and functional recovery at successive intervals. A late inflammatory marker becomes meaningful when connected to the earlier sequence.

The hypothesis predicts that patients who fail to recover should sometimes exhibit a distinct interruption in this sequence, not simply higher inflammatory intensity at every stage. This is a more discriminating claim than asserting that inflammation is excessive. The strongest evidence would show that changing the interrupted process restores tissue function without impairing microbial defense. If recovery remains limited because specialized cells are permanently lost, improving resolution might still prevent further damage but would not be expected to regenerate the organ.

Selected scientific reading

1. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. *Nature*. 2014;510:92–101.
2. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. *Nat Rev Immunol*. 2010;10:36–46.
3. Netea MG et al. Defining trained immunity and its role in health and disease. *Nat Rev Immunol*. 2020;20:375–388.

Editorial and evidentiary note

This is an expanded conceptual synthesis, not original clinical research or a clinical treatment protocol. It preserves selected references from the original edition, whose bibliographic metadata have not all been independently reverified. Claims about specific diagnoses and treatments require appropriate primary evidence and professional assessment. Mechanistic plausibility does not establish therapeutic efficacy.